Characteristics of patients at first intracameral chemotherapy (ICC): demographics, previous treatments, clinical and cytological features
| # | Patient | Study eye | Previous treatments | Aqueous seeding (AS) features | Concomitant active tumour | |||||||||||||
| Sex | Age at Dx Rb (months) | Age at Dx AS (months) | Laterality | IIRC group | AS type | IVC | IAC | IViC | BCT | Classification 1=dust 2=spheres 3=cloud | Posterior chamberinvolvement | Anterior chamber cytology | Anterior uvea invasion | Vitreous seeding | Retinal tumour | Subretinal seeding | ||
| Angular involvement in degrees | Interciliary involvement | |||||||||||||||||
| 1 | F | 132 | 132 | U | E1 | P | 0 | 0 | 0 | 0 | 2 | 360 | – | Malignant | – | + | + | – |
| 2 | M | 6 | 23 | B* | D | S | 5 | 0 | 0 | 0 | 1 | 30 | + | Atypical | Ciliary body | – | + | – |
| 3 | M | 57 | 60 | U | D | S | 3 | 0 | 0 | 0 | 2 | 60 | – | Negative | – | + | – | – |
| 4 | M | 6 | 14 | U | E | S | 1 | 3 | 0 | 0 | 2 | 360 | – | Malignant | – | – | – | – |
| 5 | M | 3 | 76 | B* | B | S | 25 | 0 | 1 | 1 | 1 | 45 | + | Malignant | – | + | + | – |
| 6 | M | 3 | 101 | B* | D | S | 26 | 0 | 2 | 2 | 2 | 30 | + | Malignant | – | + | – | – |
| 7 | F | 60 | 73 | U | D | S | 6 | 0 | 0 | 0 | 1 | 30 | – | Malignant | – | + | + | – |
| 8 | M | 4 | 26 | B* | B | S | 8 | 0 | 2 | 1 | 3 | 360 | – | Malignant | Iris+ciliary body | – | – | – |
| 9 | M | 0.1 | 259 | B | B | S | 13 | 6 | 8 | 1 | 3 | 360 | + | Malignant | – | + | – | – |
| 10 | M | 137 | 137 | B* | E2 | P | 0 | 0 | 0 | 0 | 2 | 105 | – | Malignant | – | + | + | – |
| 11 | M | 115 | 115 | U | E1 | P | 0 | 0 | 0 | 0 | 3 | 360 | – | Malignant | – | + | + | – |
| 12 | M | 12 | 50 | B | D | S | 4 | 2 | 0 | 2 | 2 | 15 | – | Negative | – | – | + | – |
| 13 | M | 23 | 28 | U | E | S | 5 | 0 | 2 | 1 | 1 | 15 | – | Negative | – | + | – | + |
| 14 | F | 161 | 161 | U | E | P | 0 | 0 | 0 | 0 | 2 | 360 | – | Malignant | – | + | + | + |
| 15 | M | 88 | 116 | U | D | S | 0 | 3 | 3 | 0 | UBM only | 90 | – | Malignant | – | + | + | – |
| 16 | F | 42 | 55 | U | C | S | 5 | 3 | 1 | 0 | UBM only | 10 | – | Negative | – | + | + | + |
| 17 | M | 53 | 58 | U | D | S | 1 | 3 | 5 | 0 | UBM only | 30 | – | Negative | – | + | – | + |
| 18 | M | 3 | 80 | B | B | S | 5 | 0 | 4 | 0 | 2 | 135 | – | Malignant | – | + | + | – |
| 19 | M | 7 | 47 | B | na | S | 6 | 5 | 0 | 0 | UBM only | 10 | – | No analysis | – | + | + | – |
| 20 | M | 2 | 56 | B | na | S | 6 | 6 | 5 | 1 | 2 | 45 | – | Malignant | – | – | – | – |
IIRC (Linn Murphree7 2005).
*Only remaining eye.
.B, bilateral; BCT, brachytherapy; Dx, diagnosis; IAC, intra-arterial chemotherapy; IIRC, International Intraocular Retinoblastoma Classification; IVC, intravenous chemotherapy; IViC, intravitreal chemotherapy; na, not available; p, primary; rb, retinoblastoma; S, secondary; U, unilateral; UBM, ultrasound biomicroscopy.